AMGN vs NBIX
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. NBIX: A neuroscience-focused biopharmaceutical company commercializing specialized treatments for neurological and endocrine disorders while advancing a diverse pipeline of therapeutic modalities.
Side-by-side fundamentals
| Metric | AMGN | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $376.26 | $176.41 | |
| Market cap as of 2026-08-02 | $203.1B | $17.9B | |
| P/E as of 2026-08-02 | 26.65 | 23.77 | NBIX lower |
| PEG as of 2026-08-02 | 5.48 | 0.27 | NBIX lower |
| Net margin as of 2026-08-02 | +21.0% | +20.9% | AMGN higher |
| Gross margin as of 2026-08-02 | +74.0% | +98.0% | NBIX higher |
| Operating margin as of 2026-08-02 | +28.8% | +23.6% | AMGN higher |
| ROE as of 2026-08-02 | +89.4% | +21.1% | AMGN higher |
| ROA as of 2026-08-02 | +8.6% | +14.7% | NBIX higher |
| Debt / equity as of 2026-08-02 | 6.24 | 0.00 | NBIX lower |
| Revenue growth (YoY) as of 2026-08-02 | +9.1% | +34.4% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +24.3% | NBIX higher |
| Dividend yield as of 2026-08-02 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-02 | 0.42 | 0.39 | |
| 1-year return as of 2026-07-27 close | +22.7% | +33.5% | NBIX higher |
Fundamentals: market data, as of 2026-08-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.